NCT04636710 is a NA clinical trial of Lymphoscintigraphy in Breast Cancer, sponsored by Dana-Farber Cancer Institute.

Who is sponsoring NCT04636710?

NCT04636710 is sponsored by Dana-Farber Cancer Institute.

What drugs are being tested in NCT04636710?

Interventions in NCT04636710: Lymphoscintigraphy.

What condition does NCT04636710 study?

NCT04636710 studies Breast Cancer, Inflammatory Breast Cancer, Sentinel Lymph Node.

Is NCT04636710 still recruiting?

NCT04636710 is currently recruiting now. Last updated 29 December 2025.

Last reviewed 2025-12-29 · How we verify

NCT04636710

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Refining Local-Regional Therapy for IBC

Recruiting now NA Last updated 29 December 2025

What this trial tests

NA trial testing Lymphoscintigraphy in Breast Cancer in 50 participants. Currently enrolling.

Timeline

2 June 2021

Primary endpoint
1 December 2027

1 December 2028

Quick facts

Lead sponsor	Dana-Farber Cancer Institute
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	50
Start date	2 June 2021
Primary completion	1 December 2027
Estimated completion	1 December 2028
Sites	1 location across United States

Drugs / interventions tested

Lymphoscintigraphy

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Inflammatory Breast Cancer — all drugs for Inflammatory Breast Cancer →
Sentinel Lymph Node — all drugs for Sentinel Lymph Node →

Sponsor

Dana-Farber Cancer Institute

Who can join

18 and older, female only, with Breast Cancer or Inflammatory Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Feasibility study is trying to determine: * If Lymphoscintigraphy (imaging of the lymphatic drainage patterns) is effective in demonstrating the drainage to the sentinel lymph nodes in patients with inflammatory breast cancer. * The likelihood of identifying the sentinel lymph nodes in the operating room, using both blue dye and the radioactive substance used for lymphoscintigraphy. * The incidence of lymphedema (arm swelling which occurs after lymph node surgery) in women with inflammatory breast cancer * Outcomes for women with inflammatory breast cancer, whether or not the sentinel lymph nodes can be identified.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Clipped Axillary Node as a Potential Surrogate for Overall Axillary Nodal Status in Inflammatory Breast Cancer Patients after Neoadjuvant Chemotherapy.
Lohani KR, Hoskin TL, Yasir S, Olson CA, et al · · 2024 · cited 2× · PMID 39120840 · DOI 10.1245/s10434-024-15796-7

Verify or expand the search:

Other trials of Lymphoscintigraphy

Trials testing the same drug.

NCT06031688 — Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung · Phase 2 · recruiting

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Dana-Farber Cancer Institute trials

Trials by the same sponsor.

NCT07519200 — Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention · NA · not yet recruiting
NCT07499999 — Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk fo · Phase 2 · not yet recruiting
NCT05825469 — Development and Testing of Nutritional Algorithms (NACHO) · NA · not yet recruiting
NCT07516353 — my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults · NA · not yet recruiting
NCT07513324 — Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04636710 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dana-Farber Cancer Institute
Last refreshed: 29 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04636710.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing